September 29, 2015 | The Israeli biomedical firm Aposense and the leading international pharmaceutical company Pfizer announced that they would enter into a research agreement. The agreement will see to the technological evaluation of Aposense’s ML-10 molecule that is able to identify apoptosis, a process of programmed cell death. Aposense was founded in 1996 by Ilan Ziv and Yaacov Gotenstein.
Related posts
Sales Insight Startup Konnecto Raises $21m Funding
June 30, 2022
Facebook comments